Photo of Diane F Jelinek

View Scopus Profile

Diane F Jelinek, PhD

  • 10851 Citations
  • 62 Scopus h-Index
1981 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Diane F Jelinek is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 28 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

MOLECULAR CLONING OF BILE ACID BIOSYNTHESIS GENES

Jelinek, D. F.

2/28/89 → …

Project: Research project

Role of lncRNAs in Clinical Heterogeneity of Early Stage IGHV Unmutated CLL

Jelinek, D. F.

9/1/15 → 8/31/17

Project: Research project

Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression

Jelinek, D. F.

7/1/15 → 6/30/20

Project: Research project

Metabolic Reprogramming: Essential Role and Early Marker of MGUS Progression

Jelinek, D. F.

8/1/12 → 7/31/14

Project: Research project

CD147 Biological Function and Role as a Biomarker of MGUS to Myeloma Progression

Jelinek, D. F.

National Institutes of Health

3/1/12 → 2/28/14

Project: Research project

    • Research Output

    Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture

    Walters, D. K. & Jelinek, D. F., Feb 1 2020, In : Journal of Histochemistry and Cytochemistry. 68, 2, p. 99-112 14 p.

    Research output: Contribution to journal › Article

    • Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

    Shanafelt, T. D., Wang, V., Kay, N. E., Hanson, C. A., O'Brien, S. M., Barrientos, J. C., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A., Mullane, M. P., Little, R. F., Erba, H. P., Stone, R. M., Litzow, M. & 1 others, Tallman, M. S., Nov 13 2019, In : Blood. 134, 1, 1 p.

    Research output: Contribution to journal › Article

    • 5 Scopus citations

    Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O'Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S. E., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A. K., Mullane, M. P., Little, R. F., Erba, H., Stone, R. M., Litzow, M. & 1 others, Tallman, M., Aug 1 2019, In : The New England journal of medicine. 381, 5, p. 432-443 12 p.

    Research output: Contribution to journal › Article

    • 60 Scopus citations

    Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia

    Tschumper, R. C., Shanafelt, T. D., Kay, N. E. & Jelinek, D. F., Jan 1 2019, In : Oncotarget. 10, 1, p. 60-75 16 p.

    Research output: Contribution to journal › Article

    • 2 Scopus citations

    Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain

    Walters, D. K., Arendt, B. K., Tschumper, R. C., Wu, X. & Jelinek, D. F., Jan 1 2018, In : Experimental Hematology. 57, p. 42-49.e1

    Research output: Contribution to journal › Article

    • 1 Scopus citations